Madrigal Pharmaceuticals Inc [MDGL] stock is trading at $407.09, up 3.94%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MDGL shares have gain 9.62% over the last week, with a monthly amount glided 32.71%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] stock has seen the most recent analyst activity on February 28, 2025, when B. Riley Securities upgraded its rating to a Buy and also boosted its price target to $422 from $236. Previously, H.C. Wainwright reaffirmed its Buy rating on February 27, 2025, and elevated its price target to $405. On June 28, 2024, Cantor Fitzgerald initiated with a Neutral rating. Wolfe Research started tracking the stock assigning a Outperform rating and suggested a price target of $382 on June 11, 2024. BofA Securities initiated its recommendation with a Underperform and recommended $150 as its price target on April 22, 2024. B. Riley Securities upgraded its rating to Neutral for this stock on March 15, 2024, and upped its price target to $270. In a note dated March 06, 2024, Citigroup initiated an Buy rating and provided a target price of $382 on this stock.
Madrigal Pharmaceuticals Inc [MDGL] stock has fluctuated between $200.63 and $393.77 over the past year. Currently, Wall Street analysts expect the stock to reach $420 within the next 12 months. Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] shares were valued at $407.09 at the most recent close of the market. An investor can expect a potential return of 3.17% based on the average MDGL price forecast.
Analyzing the MDGL fundamentals
Madrigal Pharmaceuticals Inc [NASDAQ:MDGL] reported sales of 515.55M for the trailing twelve months, which represents a growth of 1353.76%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -0.6%, Pretax Profit Margin comes in at -0.55%, and Net Profit Margin reading is -0.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.38 and Total Capital is -0.38. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 395.20 points at the first support level, and at 383.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 416.74, and for the 2nd resistance point, it is at 426.39.
Ratios To Look Out For
For context, Madrigal Pharmaceuticals Inc’s Current Ratio is 5.11. As well, the Quick Ratio is 4.78, while the Cash Ratio is 0.97. Considering the valuation of this stock, the price to sales ratio is 17.60, the price to book ratio is 13.00.
Transactions by insiders
Recent insider trading involved Sibold William John, President and CEO, that happened on Aug 21 ’25 when 7616.0 shares were sold. Director, WILLIAM SIBOLD completed a deal on Aug 21 ’25 to buy 7616.0 shares. Meanwhile, Director BAKER BROS. ADVISORS LP bought 59901.0 shares on Aug 20 ’25.
